MX2024003537A - Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina. - Google Patents
Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina.Info
- Publication number
- MX2024003537A MX2024003537A MX2024003537A MX2024003537A MX2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- subject
- treating
- cedazuridine
- decitabine
- Prior art date
Links
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title abstract 6
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 title abstract 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 title abstract 2
- 229940063170 cedazuridine Drugs 0.000 title abstract 2
- 229960003603 decitabine Drugs 0.000 title abstract 2
- 230000004083 survival effect Effects 0.000 abstract 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 abstract 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 abstract 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 abstract 1
- 229940075628 hypomethylating agent Drugs 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246547P | 2021-09-21 | 2021-09-21 | |
| PCT/US2022/076757 WO2023049731A2 (en) | 2021-09-21 | 2022-09-21 | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003537A true MX2024003537A (es) | 2024-05-03 |
Family
ID=85721229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003537A MX2024003537A (es) | 2021-09-21 | 2022-09-21 | Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250000888A1 (https=) |
| EP (1) | EP4404940A4 (https=) |
| JP (1) | JP2024531799A (https=) |
| KR (1) | KR20240064656A (https=) |
| CN (1) | CN118201622A (https=) |
| AU (1) | AU2022348907A1 (https=) |
| CA (1) | CA3232623A1 (https=) |
| MX (1) | MX2024003537A (https=) |
| TW (1) | TW202327625A (https=) |
| WO (1) | WO2023049731A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4704834A1 (en) * | 2023-05-02 | 2026-03-11 | Taiho Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2649997B1 (en) * | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
| WO2016085876A1 (en) * | 2014-11-25 | 2016-06-02 | The Broad Institute Inc. | Clonal haematopoiesis |
| US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| JP2023504515A (ja) * | 2019-12-05 | 2023-02-03 | スミトモ ファーマ オンコロジー， インコーポレイテッド | 骨髄異形成症候群の処置のための併用療法 |
| JP2023510393A (ja) * | 2020-01-17 | 2023-03-13 | ノバルティス アーゲー | 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ |
| PH12022552250A1 (en) * | 2020-02-25 | 2023-11-13 | Otsuka Pharma Co Ltd | Combination decitabine and cedazuridine solid oral dosage forms |
-
2022
- 2022-09-21 WO PCT/US2022/076757 patent/WO2023049731A2/en not_active Ceased
- 2022-09-21 TW TW111135794A patent/TW202327625A/zh unknown
- 2022-09-21 KR KR1020247010215A patent/KR20240064656A/ko active Pending
- 2022-09-21 US US18/693,727 patent/US20250000888A1/en active Pending
- 2022-09-21 CA CA3232623A patent/CA3232623A1/en active Pending
- 2022-09-21 CN CN202280073476.0A patent/CN118201622A/zh active Pending
- 2022-09-21 JP JP2024517163A patent/JP2024531799A/ja active Pending
- 2022-09-21 MX MX2024003537A patent/MX2024003537A/es unknown
- 2022-09-21 AU AU2022348907A patent/AU2022348907A1/en active Pending
- 2022-09-21 EP EP22873816.7A patent/EP4404940A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022348907A1 (en) | 2024-04-11 |
| WO2023049731A2 (en) | 2023-03-30 |
| WO2023049731A3 (en) | 2023-05-04 |
| JP2024531799A (ja) | 2024-08-29 |
| EP4404940A2 (en) | 2024-07-31 |
| US20250000888A1 (en) | 2025-01-02 |
| CA3232623A1 (en) | 2023-03-30 |
| TW202327625A (zh) | 2023-07-16 |
| CN118201622A (zh) | 2024-06-14 |
| EP4404940A4 (en) | 2025-07-30 |
| KR20240064656A (ko) | 2024-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000151A (es) | Composiciones y usos de las mismas para el tratamiento de afecciones malignas de celulas t usando terapias de celulas adoptivas. | |
| DOP2020000050A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
| MX2022006365A (es) | Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos. | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| CO2020004906A2 (es) | Composiciones y métodos para la eliminación de células cd117+ | |
| MX2021015993A (es) | Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico. | |
| CO6470858A2 (es) | Composición tensioactiva reconstituida mejorada que contiene análogos de la proteína tensioactiva b (sp-b) y de la proteína tensioactiva c (sp-c) | |
| MX375746B (es) | Combinación de lenalidomida y constructo de polipéptido, y sus usos. | |
| CO6331301A2 (es) | Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa | |
| MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
| CR20170406A (es) | Arni variante | |
| MX2017000578A (es) | Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico. | |
| CL2019000190A1 (es) | Tratamiento y prevención de los trastornos del sueño. | |
| MX2019015204A (es) | Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda. | |
| MX336884B (es) | Expresión de il 1rap en leucemia. | |
| ECSP20057847A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| MX2015012536A (es) | Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. | |
| AR112103A1 (es) | Compuestos para el tratamiento de tnbc | |
| MX2024003537A (es) | Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina. | |
| MX2021005734A (es) | Metodos de dosificacion de celulas t modificadas para el tratamiento de malignidades de celulas b. | |
| MX390835B (es) | Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientes | |
| MX2021004329A (es) | 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos. | |
| MX2024009575A (es) | Compuestos con estructura en t formada por al menos cuatro ciclos para usar en el tratamiento del cáncer y otras indicaciones. | |
| MX2019014330A (es) | Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax. |